LifeTech Capital Maintains Strong Buy Rating and $4.75 PT on Oculus Innovative Sciences
A report from LifeTech Capital reiterates its Strong Buy rating and $4.75 price target on Oculus Innovative Sciences (NASDAQ: OCLS).
The report states, “Investors should note that top line sales and gross margins will experience seasonal fluctuations as the equine animal health business decreases during the winter months. To mitigate this, the company is working on expanding its companion animal (cats and dogs) presence as well as the development of new products for animal livestock that are less correlated to seasonal changes."
OCLS closed yesterday at $1.47.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.